SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2024)
SAB Biotherapeutics (SABS) reported EBITDA Margin of 8726.26% for Q4 2024, down 253836.0% on a YoY basis from N/an in Q1 2024, and down 125.08% quarter-over-quarter from 3876.95% in Q2 2024.
SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics has reported EBITDA Margin for 4 years, with the latest figure at 8726.26% in Q4 2024.
- For the quarter ending Q4 2024, EBITDA Margin fell 253836.0% year-over-year to 8726.26%; the trailing twelve-month figure through Dec 2024 stood at 3244.87% (down 154432.0% YoY), and the FY2024 full-year result was 2591.26%, down 89071.0% from the prior year.
- EBITDA Margin for Q4 2024 stood at 8726.26%, down from 3876.95% in the prior quarter.
- The five-year high for EBITDA Margin was 792.62% in Q4 2022, with the low at 8726.26% in Q4 2024.
- Historically, EBITDA Margin has averaged 1930.23% across 4 years, with a median of 217.49% in 2022.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 747037 bps — and 2024, when it soared 369644 bps.
- SAB Biotherapeutics' EBITDA Margin stood at 66.41% in 2021, then jumped by 1293 bps to 792.62% in 2022, then plunged by 881 bps to 6187.9% in 2023, then sank by 41 bps to 8726.26% in 2024.
- The last three EBITDA Margin figures came in at 8726.26% (Q4 2024), 3876.95% (Q2 2024), and 1205.9% (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8,726.26% |
| Jun 30, 2024 | -3,876.95% |
| Mar 31, 2024 | -1,205.90% |
| Dec 31, 2023 | -6,187.90% |
| Sep 30, 2023 | -420.00% |
| Jun 30, 2023 | -7,573.40% |
| Mar 31, 2023 | -1,273.79% |
| Dec 31, 2022 | 792.62% |
| Sep 30, 2022 | -217.49% |
| Jun 30, 2022 | -103.03% |
| Mar 31, 2022 | -56.83% |
| Dec 31, 2021 | -66.41% |
| Sep 30, 2021 | -27.18% |
| Jun 30, 2021 | -15.77% |
| Mar 31, 2021 | 4.81% |